Álvarez Fernando, Arena Maria, Auteri Domenica, Batista Leite Sofia, Binaglia Marco, Castoldi Anna Federica, Chiusolo Arianna, Cioca Ana-Andreea, Colagiorgi Angelo, Colas Mathilde, Crivellente Federica, De Lentdecker Chloe, De Magistris Isabella, Egsmose Mark, Fait Gabriella, Ferilli Franco, Gouliarmou Varvara, Halling Katrin, Herrero Nogareda Laia, Ippolito Alessio, Istace Frederique, Jarrah Samira, Kardassi Dimitra, Kienzler Aude, Lanzoni Anna, Lava Roberto, Leuschner Renata, Linguadoca Alberto, Louisse Jochem, Lythgo Christopher, Magrans Oriol, Mangas Iris, Miron Ileana, Molnar Tunde, Padovani Laura, Padricello Vincenzo, Panzarea Martina, Parra Morte Juan Manuel, Rizzuto Simone, Romac Anamarija, Rortais Agnès, Serafimova Rositsa, Sharp Rachel, Szentes Csaba, Terron Andrea, Theobald Anne, Tiramani Manuela, Vianello Giorgia, Villamar-Bouza Laura
EFSA J. 2023 Aug 9;21(8):e08196. doi: 10.2903/j.efsa.2023.8196. eCollection 2023 Aug.
The conclusions of the EFSA following the peer review of the initial risk assessments carried out by the competent authorities of the rapporteur Member State, Belgium, and co-rapporteur Member State, Greece, for the pesticide active substance mepanipyrim are reported. The context of the peer review was that required by Commission Implementing Regulation (EU) No 844/2012. The conclusions were reached on the basis of the evaluation of the representative uses of mepanipyrim as a fungicide on table and wine grapes and in field and protected strawberries and tomatoes. The conclusions were updated with regard to the endocrine-disrupting properties following a mandate received from the European Commission in January 2019. The reliable end points appropriate for use in regulatory risk assessment are presented. Missing information identified as being required by the regulatory framework is listed. Concerns are reported where identified.
报告了欧洲食品安全局（EFSA）对报告成员国比利时和共同报告成员国希腊的主管当局针对农药活性物质嘧菌胺开展的初始风险评估进行同行评审后的结论。同行评审的背景是委员会实施条例（欧盟）第844/2012号所要求的。这些结论是在对嘧菌胺作为杀菌剂在鲜食葡萄和酿酒葡萄以及露地和设施草莓及番茄上的代表性用途进行评估的基础上得出的。根据2019年1月从欧盟委员会获得的一项任务授权，对内分泌干扰特性方面的结论进行了更新。列出了适用于监管风险评估的可靠终点。列出了监管框架要求的但发现缺失的信息。报告了已识别出的问题。
